CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Endovascular products.

CeloNova is hiring a Vice President, Business Development, with an estimated salary of $250000 - $2147483647. This Sales Management & Operations job in Sales & Business Development is in San Oct 27, 2017 · CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's ongoing clinical trial of its proprietary Cobra PzF NanoCoated Coronary Stent (NCS) with 14-day dual antiplatelet therapy (DAPT) in complex patients, such as those who are at high bleeding risk. The COBRA REDUCE trial is the world's first and only randomized control trial to assess August 6, 2019 – CeloNova BioSciences, Inc. (CeloNova), a global medical device company and manufacturer of the proprietary Polyzene™-F nanocoating technology, currently used to surface coat its novel COBRA PzF NanoCoated Coronary Stent (NCS), today announced appointment of seasoned medical device executive Carl J. St. Bernard as President and Chief Executive Officer to support the company Mar 10, 2014 · CeloNova BioSciences develops, manufactures and markets various interventional cardiology and endovascular products. It employs about 150 workers, with 25 to 35 in San Antonio, Landon said. Oct 30, 2014 · CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Endovascular Electrode, Comp-888373659, DC-prod-az-southcentralus-14, ENV-prod-a, PROF-PROD, VER-20.0.26, SHA-17ebb73d7c865c83106a9dc51a9155d82f2381f9, CID-9d912fd5-0e7

CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Endovascular products.

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial. The COBRA REDUCE randomized control trial is a first-of-its-kind study designed to evaluate ultra-short DAPT in PCI patients at high bleeding risk with COBRA PzF NCS with 14-day DAPT compared to drug-eluting stents with 3 or 6 months DAPT. CeloNova BioSciences, Inc. is an innovative global medical device leader transforming the treatment of cardiovascular disease and promoting positive outcomes in patients around the world. CeloNova CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Endovascular products. Nov 10, 2015 · CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of interventional cardiology and endovascular products, including its proprietary COBRA PzF™ Coronary Stent System.

www.celonova.com: Choose Language: eCaselink comments/questions? Please use any of the following methods to access DSG Technical Support.

4 Celonova Pl is a house in Lake Forest, CA 92610. This 2,882 square foot house sits on a 6,236 square foot lot and features 5 bedrooms and 3 bathrooms. This property was built in 1996 and last sold on June 21, 2019 for $1,100,000.